Kinesin inhibitor, NMS-P715, Purity ≥98%

Synonym: 1202055-32-0; NMSP715; NMS P715; N-(2,6-Diethylphenyl)-1-methyl-8-[4-[(1-methylpiperidin-4-yl)carbamoyl]-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide

CAS Number: 1202055-32-0
Compound CID: 44556162

Product Size

5 mg; 10 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

NMS-P715 is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting kinesin. It targets the CK2, MELK, Mps1, and NEK6.

Molecular Weight

676.73

Molecular Formula

C₃₅H₃₉F₃N₈O₃

Targets

CK2: 5.7 μM (IC₅₀); MELK: 6.01 μM (IC₅₀); Mps1: 182 nM (IC₅₀); NEK6: 6.02 μM (IC₅₀)

Form

Lyophilized powder

Purity

≥98%

Titer

Free from inappropriate visible particulates, foreign matter, discoloration, or other defects

Applications

NMS-P715 is a cytoskeletal signaling inhibitor that can be used for its ability to disrupt protein degradation pathways, leading to accumulation of pro-apoptotic factors and induction of cancer cell death.